BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Smith T, Samandari T, Abimbola T, Marston B, Sangrujee N. Implementation and Operational Research: Cost-Effectiveness of Antiretroviral Therapy and Isoniazid Prophylaxis to Reduce Tuberculosis and Death in People Living With HIV in Botswana. J Acquir Immune Defic Syndr 2015;70:e84-93. [PMID: 26258564 DOI: 10.1097/QAI.0000000000000783] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Cunnama L, Gomez GB, Siapka M, Herzel B, Hill J, Kairu A, Levin C, Okello D, DeCormier Plosky W, Garcia Baena I, Sweeney S, Vassall A, Sinanovic E. A Systematic Review of Methodological Variation in Healthcare Provider Perspective Tuberculosis Costing Papers Conducted in Low- and Middle-Income Settings, Using An Intervention-Standardised Unit Cost Typology. Pharmacoeconomics 2020;38:819-37. [PMID: 32363543 DOI: 10.1007/s40273-020-00910-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
2 Campa A, Baum MK, Bussmann H, Martinez SS, Farahani M, van Widenfelt E, Moyo S, Makhema J, Essex M, Marlink R. The effect of micronutrient supplementation on active TB incidence early in HIV infection in Botswana. Nutr Diet Suppl 2017;2017:37-45. [PMID: 29187783 DOI: 10.2147/NDS.S123545] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
3 Uppal A, Rahman S, Campbell JR, Oxlade O, Menzies D. Economic and modeling evidence for tuberculosis preventive therapy among people living with HIV: A systematic review and meta-analysis. PLoS Med 2021;18:e1003712. [PMID: 34520463 DOI: 10.1371/journal.pmed.1003712] [Reference Citation Analysis]
4 Pathmanathan I, Ahmedov S, Pevzner E, Anyalechi G, Modi S, Kirking H, Cavanaugh JS. TB preventive therapy for people living with HIV: key considerations for scale-up in resource-limited settings. Int J Tuberc Lung Dis 2018;22:596-605. [PMID: 29862942 DOI: 10.5588/ijtld.17.0758] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 10.5] [Reference Citation Analysis]
5 Shayo GA, Chitama D, Moshiro C, Aboud S, Bakari M, Mugusi F. Cost-Effectiveness of isoniazid preventive therapy among HIV-infected patients clinicaly screened for latent tuberculosis infection in Dar es Salaam, Tanzania: A prospective Cohort study. BMC Public Health 2017;18:35. [PMID: 28724374 DOI: 10.1186/s12889-017-4597-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
6 Gopalan N, Chandrasekaran P, Swaminathan S, Tripathy S. Current trends and intricacies in the management of HIV-associated pulmonary tuberculosis. AIDS Res Ther 2016;13:34. [PMID: 27708678 DOI: 10.1186/s12981-016-0118-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]